Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rubitecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 3/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rubitecan SCHEMBL29379605 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29383355 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL6426025 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL15539941 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL1652417 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28223445 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27953003 | 0.98 | ABCC4 (0.95) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28308474 | 0.96 | ABCC4 (0.93) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27598505 | 0.94 | ABCC3 (0.89) | ABCC4HTTABCC3ACHEPTGS1 | |
| SCHEMBL25932527 | 0.92 | ABCC4 (0.85) | ABCC4HTTABCC3ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23871 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144890-A1 | ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR CONJUGATED TO AN ANTIBODY | MyricX Pharma Limited (GB) | 2026-05-28 | — | — | US | claimed |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026098633-A1 | CONJUGATES AND USES THEREOF | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090139-A1 | ANTI-LY6K ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NORMUNITY, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4732850-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Antelope Therapeutics SAS (FR) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-5922877-A | HIGHER YIELD WITHOUT NUMEROUS BYPRODUCTS, USE IN TREATING CANCER | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 1999-07-13 | — | — | US | claimed |
| WO-1999017804-A1 | POLYMERIC DERIVATIVES OF CAMPTOTHECINS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-04-15 | — | — | WO | claimed |
| WO-1999015153-A1 | SMALL PARTICLE LIPOSOME AEROSOLS FOR DELIVERY OF ANTI-CANCER DRUGS | RESEARCH DEVELOPMENT FOUNDATION (US) | 1999-04-01 | — | — | WO | claimed |
| WO-1999007709-A1 | METHODS OF PREPARING AND PURIFYING 9-NITRO-20-CAMPTOTHECIN | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 1999-02-18 | — | — | WO | claimed |
| US-5786344-A | ADMINISTERING WITH AGENT WHICH INCREASES ACTIVITY OF GLUCURONOSYLTRANSFERASE OR DECREASES ACTIVITY OF BILIARY TRANSPORT PROTEIN | ARCH DEVELOPMENT CORPORATION (US) | 1998-07-28 | — | — | US | claimed |
| US-5736156-A | ANTICARCINOGENIC AGENT HAVING LACTONE RING PROTECTED FROM HYDROLYSIS BY ASSOCIATION WITH SURFACTANT OR LIPID; DRUG DELIVERY, WATER SOLUBILITY, NONTOXIC | THE OHIO STATE UNIVERSITY (US) | 1998-04-07 | — | — | US | claimed |
| EP-0768895-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1997-04-23 | — | — | EP | claimed |
| US-5552156-A | ANTITUMOR AGENTS | OHIO STATE UNIVERSITY (US) | 1996-09-03 | — | — | US | claimed |
| WO-1996001127-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-18 | — | — | WO | claimed |
| CN-1113384-A | Preparation method of 9-amino camptothecin | PHARMACIA SPA (IT) | 1995-12-13 | — | — | CN | claimed |